Ceftazidime vs 7 days injectable benzylpenicillin + injectable gentamicin
All‐cause mortality maximum · neonates with early‐onset sepsis
1 finding from 1 review
- no estimate extracted1 study · 55 participantsVery low
Findings
What do systematic reviews say?
9 questions · 9 findings · 2 reviews
No studies found 1 · 11.1%GRADE not reported 0 · 0%Very low 2 · 22.2%Low 0 · 0%Moderate 1 · 11.1%High 5 · 55.6%
Ceftazidime vs 7 days injectable benzylpenicillin + injectable gentamicin
Serious adverse events maximum · neonates with early‐onset sepsis
1 finding from 1 review
- no estimate extracted1 study · 55 participantsVery low
Intravenous ceftazidime with tobramycin vs ciprofloxacin
Eradication of P aeruginosa from the respiratory tract: number of participants testing negative for P aeruginosa at 3 months and remaining free until 15 months · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
- Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Intravenous ceftazidime with tobramycin vs ciprofloxacin
FEV1 % predicted · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
- Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes onlyno estimate extracted1 study · 285 participantsHigh
Intravenous ceftazidime with tobramycin vs ciprofloxacin
FVC · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
- Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes onlyno estimate extracted1 study · 285 participantsHigh
Intravenous ceftazidime with tobramycin vs ciprofloxacin
Mean weight‐for‐age z‐score · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
- Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes onlyno estimate extracted1 study · 285 participantsHigh
Intravenous ceftazidime with tobramycin vs ciprofloxacin
Frequency of infective pulmonary exacerbations: number of participants experiencing an exacerbation · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Intravenous ceftazidime with tobramycin showed no clear difference in frequency of infective pulmonary exacerbations: number of… compared with oral ciprofloxacin (high certainty).
1 finding from 1 review
- Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes onlyRR 0.78 [0.55, 1.1]1 study · 285 participantsHigh
Intravenous ceftazidime with tobramycin vs ciprofloxacin
Isolation of other micro‐organisms from the respiratory tract: number of participants isolating other micro‐organisms within the 15‐month · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Intravenous ceftazidime with tobramycin leads to higher isolation of other micro‐organisms from the respiratory tract:… compared with oral ciprofloxacin (high certainty).
1 finding from 1 review
- Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes onlyRR 2.071 study · 285 participantsHigh
Intravenous ceftazidime with tobramycin vs ciprofloxacin
Adverse effects of antibiotics · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Intravenous ceftazidime with tobramycin probably leads to lower adverse effects of antibiotics: compared with oral ciprofloxacin (moderate certainty).
1 finding from 1 review
- Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes onlyRR 0.971 study · 285 participantsModerate